Histone modification regulation method based on placenta amnion sub-totipotent stem cells and anti-aging preparation thereof

By screening for histone modification targets MLL3 and JMJD3 in placental amniotic pluripotent stem cells, and employing compound small molecule regulators and optimized formulation design, the problems of imprecise histone modification regulation and short-term stem cell activity maintenance in existing technologies have been solved, achieving highly efficient and safe anti-aging effects and long-term in vivo survival.

CN121896155APending Publication Date: 2026-04-21NINGXIA TAINUO KANGZHONG BIOTECHNOLOGY CO LTD
0 Cites 0 Cited by

Patent Information

Application Number
CN202610045593.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-01-14
Publication Date
2026-04-21

AI Technical Summary

Technical Problem

Existing anti-aging technologies based on placental amniotic pluripotent stem cells suffer from low precision in histone modification regulation, short duration of stem cell activity maintenance, unstable anti-aging effects, and high potential immune risks. Current technologies lack precise regulatory methods and safe formulation design.

Method used

By screening specific histone modification regulatory targets MLL3 and JMJD3, and using the combined small molecule regulators CM-272 and GSK-J4, along with optimized stem cell culture and formulation preparation techniques, a histone modification regulation method and its anti-aging formulation were constructed. Using sodium alginate-gelatin composite carrier and mannitol human serum albumin protectant, an injectable anti-aging formulation was prepared.

Benefits of technology

It achieves precise regulation of histone modification status in stem cells, significantly enhances stem cell activity and anti-aging gene expression levels, prolongs stem cell survival time in vivo, reduces the risk of immune rejection, and provides highly effective and safe anti-aging effects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to the technical field of stem cell engineering and anti-aging biology, in particular to a histone modification regulation method based on placenta amnion sub-totipotent stem cells and an anti-aging preparation thereof. The regulation and control method comprises the following steps: separating and purifying healthy full-month caesarean section placenta amniotic membrane tissues, carrying out composite enzymolysis and flow cytometry screening to obtain CD105 < + >, CD73 < + > and CD45 <-> stem cells, and primarily culturing the CD105 < + >, CD73 < + > and CD45 <-> stem cells; the method comprises the following steps: determining histone methyltransferase MLL3 and demethylase JMJD3 as target spots through ChIP-seq, and determining H3K4me3 and H3K27me3 as target modification sites; an MLL3 activator CM-272 with the final concentration of 15 [mu] M and a JMJD3 inhibitor GSK-J4 with the final concentration of 10 [mu] M form a composite regulator, and induction culture is performed for 84 h under the conditions of 37 DEG C and 5% CO2; and carrying out Western Blot verification and screening on the stem cells meeting the standard. According to the anti-aging preparation, regulated stem cells are used as active ingredients, a sodium alginate-gelatin (2: 1) composite carrier, 5% mannitol and 1% human serum albumin protective agent are used as auxiliary materials, and the injection with the pH of 7.2-7.4 is prepared. The method is accurate in regulation and control, and the preparation is remarkable in anti-aging effect and low in immunological rejection risk.
Need to check novelty before this filing date? Find Prior Art